Xin Lang Cai Jing·2025-05-13 10:36Core Viewpoint - The bidding price for influenza vaccines in Shenzhen has reached a historical low, with the winning bid for a trivalent influenza vaccine set at 8 yuan per dose, significantly impacting the competitive landscape of the vaccine market [1][6]. Group 1: Bidding Results - The winning supplier, Fosun Yalifeng, won the bid for 1.6 million doses of the trivalent influenza vaccine at a price of 8 yuan per dose [1][6]. - Other bidders included Changchun Biological Products Institute and Beijing Kexing, with bids of 8.35 yuan and 8.8 yuan per dose, respectively, all below 9 yuan [1][6]. - In comparison, the winning bid for a similar vaccine in Zhejiang province was 9.4 yuan per dose, indicating a regional price disparity [4]. Group 2: Competitive Landscape - The price competition among vaccine manufacturers has intensified, with many players in the market leading to price reductions as a key competitive factor [6][8]. - The scoring criteria for the bidding process included price, technical aspects, business components, integrity, and overall strength, with price accounting for 30% of the total score [6][8]. - The price war has also affected the financial performance of related companies, with significant profit declines reported, such as a 76% drop in net profit for Hualan Biological and a widening loss for Jindike [9].